慢肝康丸对肝郁脾虚型慢性乙型肝炎患者细胞免疫功能的影响

Impact of Mangankang Pill on Cellular Immune Function to Patients with Liver Stagnation and Spleen Deficiency Syndrome in Chronic Hepatitis B

摘要:

目的: 观察慢肝康丸对肝郁脾虚证慢乙肝(CHB)患者细胞免疫功能的影响。方法: 将71例中医辨证属肝郁脾虚证慢性乙肝患者随机分为治疗组和对照组,其中治疗组36例,对照组35例。两组都给予拉米夫定联合阿德福韦酯片抗病毒治疗,治疗组在对照组基础上加用慢肝康丸口服,6 g/次,3次/d,疗程共8周。结果: 治疗前后比较表明,两组在对患者肝区疼痛或不适、纳差、乏力、腹胀症状的改善方面均有一定的效果,但治疗组在改善上述症状方面明显优于对照组(P<0.05);丙氨酸转氨酶(ALT),天冬氨酸转氨酶(AST)两组间比较差异无统计学意义,在降低乙肝病毒(HBV)-DNA方面,治疗组较对照组为优(P<0.05);治疗组在治疗后CD3⁺,CD4⁺升高,CD8⁺下降,CD4⁺/CD8⁺升高,与对照组相比差异有统计学意义(P<0.05)。结论: 慢肝康丸可改善肝郁脾虚证慢乙肝患者细胞免疫紊乱状态,提高抗病毒治疗效果。

Abstract:

Objective: Observed the impact of Mangankang pill to the patients with liver stagnation and spleen deficiency syndrome in chronic hepatitis B(CHB) cellular immune function. Method: Seventy-one patients with chronic hepatitis B were enrolled and randomized into two groups:the treated group(36 cases)and the control group(35 cases).The two groups were given lamivudine treatment,the treatment group was given Mangankang pill,6 g/times, 3 times/day, with a course of eight weeks. Result: The two groups can improve liver pain or discomfort, anorexia,fatigue, bloating symptoms,the treatment group better than the control group(P<0.05).No significant difference between the two groups in the improvement of alanine aminotrans ferase(ALT) and aspartate aminotrans ferase(AST).The treatment group was more significant in the reduction of hepatitis B virus(HBV)-DNA (P<0.05).Treatment group CD3⁺,CD4⁺ increased,CD8 decreased,CD4⁺/CD8⁺ increased after treatment.Differencebwas statistically significant compared with the controlngroup(P<0.05). Conclusion: Mangankang pill can improve the status of liver stagnation and spleen deficiency syndrome in patients with chronic hepatitis B-free cellular immune disorders, improve the therapeutic effect of anti-viral.